Analysts at National Securities started coverage on shares of Urogen Pharma (NASDAQ:URGN) in a note issued to investors on Thursday, The Fly reports. The brokerage set a “neutral” rating on the stock.
Other analysts have also issued reports about the company. Zacks Investment Research raised Urogen Pharma from a “sell” rating to a “hold” rating in a research note on Saturday, October 26th. Oppenheimer cut their price target on Urogen Pharma from $70.00 to $62.00 in a research note on Wednesday, November 13th. Stifel Nicolaus set a $41.00 price target on Urogen Pharma and gave the company a “buy” rating in a research note on Sunday, October 20th. Cowen reissued a “buy” rating on shares of Urogen Pharma in a research note on Monday, November 11th. Finally, JPMorgan Chase & Co. decreased their price objective on Urogen Pharma from $40.00 to $39.00 and set a “neutral” rating for the company in a report on Wednesday, November 13th. Four equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Urogen Pharma has a consensus rating of “Buy” and a consensus price target of $51.86.
Shares of NASDAQ URGN opened at $32.23 on Thursday. Urogen Pharma has a 52 week low of $20.72 and a 52 week high of $55.13. The stock has a market capitalization of $661.39 million, a P/E ratio of -6.71 and a beta of 1.33. The stock’s fifty day moving average is $32.43 and its 200 day moving average is $30.34.
Urogen Pharma (NASDAQ:URGN) last released its earnings results on Tuesday, November 12th. The company reported ($1.06) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($1.26) by $0.20. Research analysts anticipate that Urogen Pharma will post -4.82 earnings per share for the current year.
In related news, CEO Elizabeth A. Barrett purchased 1,548 shares of the firm’s stock in a transaction that occurred on Friday, November 15th. The stock was acquired at an average price of $26.00 per share, for a total transaction of $40,248.00. Following the completion of the acquisition, the chief executive officer now owns 1,548 shares of the company’s stock, valued at approximately $40,248. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Mark Schoenberg purchased 1,960 shares of the firm’s stock in a transaction that occurred on Tuesday, November 19th. The shares were bought at an average price of $28.17 per share, with a total value of $55,213.20. The disclosure for this purchase can be found here. Insiders have purchased 10,978 shares of company stock valued at $304,621 in the last quarter. 10.50% of the stock is currently owned by corporate insiders.
A number of institutional investors have recently made changes to their positions in the stock. BlackRock Inc. grew its holdings in Urogen Pharma by 216.8% during the second quarter. BlackRock Inc. now owns 1,338,553 shares of the company’s stock worth $48,107,000 after buying an additional 915,970 shares in the last quarter. Wildcat Capital Management LLC grew its holdings in Urogen Pharma by 25.2% during the third quarter. Wildcat Capital Management LLC now owns 1,056,062 shares of the company’s stock worth $25,166,000 after buying an additional 212,697 shares in the last quarter. Highline Capital Management L.P. grew its holdings in Urogen Pharma by 2.8% during the second quarter. Highline Capital Management L.P. now owns 1,014,078 shares of the company’s stock worth $36,446,000 after buying an additional 27,200 shares in the last quarter. Phoenix Holdings Ltd. bought a new stake in Urogen Pharma during the third quarter worth $15,475,000. Finally, FMR LLC grew its holdings in Urogen Pharma by 5.8% during the first quarter. FMR LLC now owns 588,203 shares of the company’s stock worth $21,728,000 after buying an additional 32,200 shares in the last quarter. Institutional investors and hedge funds own 69.64% of the company’s stock.
About Urogen Pharma
UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing novel therapies for urological pathologies. The company's lead product candidates, UGN-101 and UGN-102 are proprietary formulations of the chemotherapy drug mitomycin, a generic drug, which is currently used off-label for urothelial cancer treatment in a water-based formulation as an adjuvant or supplemental in post-surgery therapy.
Recommended Story: Price-Sales Ratio
Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.